208 related articles for article (PubMed ID: 38022580)
1. CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma.
Ciulean IS; Fischer J; Quaiser A; Bach C; Abken H; Tretbar US; Fricke S; Koehl U; Schmiedel D; Grunwald T
Front Immunol; 2023; 14():1290488. PubMed ID: 38022580
[TBL] [Abstract][Full Text] [Related]
2. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
Front Immunol; 2019; 10():3123. PubMed ID: 32117200
[TBL] [Abstract][Full Text] [Related]
3. CD44v6-targeted CAR T-cells specifically eliminate CD44 isoform 6 expressing head/neck squamous cell carcinoma cells.
Haist C; Schulte E; Bartels N; Bister A; Poschinski Z; Ibach TC; Geipel K; Wiek C; Wagenmann M; Monzel C; Scheckenbach K; Hanenberg H
Oral Oncol; 2021 May; 116():105259. PubMed ID: 33895463
[TBL] [Abstract][Full Text] [Related]
4. CDX2 enhances natural killer cell-mediated immunotherapy against head and neck squamous cell carcinoma through up-regulating CXCL14.
Wang H; Nan S; Wang Y; Xu C
J Cell Mol Med; 2021 May; 25(10):4596-4607. PubMed ID: 33733587
[TBL] [Abstract][Full Text] [Related]
5. Memory-like Differentiation, Tumor-Targeting mAbs, and Chimeric Antigen Receptors Enhance Natural Killer Cell Responses to Head and Neck Cancer.
Jacobs MT; Wong P; Zhou AY; Becker-Hapak M; Marin ND; Marsala L; Foster M; Foltz JA; Cubitt CC; Tran J; Russler-Germain DA; Neal C; Kersting-Schadek S; Chang L; Schappe T; Pence P; McClain E; Zevallos JP; Rich JT; Paniello RC; Jackson RS; Pipkorn P; Adkins DR; DeSelm CJ; Berrien-Elliott MM; Puram SV; Fehniger TA
Clin Cancer Res; 2023 Oct; 29(20):4196-4208. PubMed ID: 37556118
[TBL] [Abstract][Full Text] [Related]
6. Natural killer cells have a synergistic anti-tumor effect in combination with chemoradiotherapy against head and neck cancer.
Jung EK; Chu TH; Vo MC; Nguyen HPQ; Lee DH; Lee JK; Lim SC; Jung SH; Yoon TM; Yoon MS; Cho D; Lee JJ; Cho HH
Cytotherapy; 2022 Sep; 24(9):905-915. PubMed ID: 35778350
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study.
Papa S; Adami A; Metoudi M; Beatson R; George MS; Achkova D; Williams E; Arif S; Reid F; Elstad M; Beckley-Hoelscher N; Douri A; Delord M; Lyne M; Shivapatham D; Fisher C; Hope A; Gooljar S; Mitra A; Gomm L; Morton C; Henley-Smith R; Thavaraj S; Santambrogio A; Andoniadou C; Allen S; Gibson V; Cook GJR; Parente-Pereira AC; Davies DM; Farzaneh F; Schurich A; Guerrero-Urbano T; Jeannon JP; Spicer J; Maher J
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37321663
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of natural killer cell therapy combined with chemoradiotherapy in murine models of head and neck squamous cell carcinoma.
Jung EK; Chu TH; Kim SA; Vo MC; Nguyen VT; Lee KH; Jung SH; Yoon M; Cho D; Lee JJ; Yoon TM
Cytotherapy; 2024 Mar; 26(3):242-251. PubMed ID: 38142382
[TBL] [Abstract][Full Text] [Related]
9. CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice.
Porcellini S; Asperti C; Corna S; Cicoria E; Valtolina V; Stornaiuolo A; Valentinis B; Bordignon C; Traversari C
Front Immunol; 2020; 11():99. PubMed ID: 32117253
[TBL] [Abstract][Full Text] [Related]
10. Efficient and Robust NK-Cell Transduction With Baboon Envelope Pseudotyped Lentivector.
Colamartino ABL; Lemieux W; Bifsha P; Nicoletti S; Chakravarti N; Sanz J; Roméro H; Selleri S; Béland K; Guiot M; Tremblay-Laganière C; Dicaire R; Barreiro L; Lee DA; Verhoeyen E; Haddad E
Front Immunol; 2019; 10():2873. PubMed ID: 31921138
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
[TBL] [Abstract][Full Text] [Related]
12. CAR-NK Cells Targeting HER1 (EGFR) Show Efficient Anti-Tumor Activity against Head and Neck Squamous Cell Carcinoma (HNSCC).
Nowak J; Bentele M; Kutle I; Zimmermann K; Lühmann JL; Steinemann D; Kloess S; Koehl U; Roßberg W; Ahmed A; Schaudien D; Neubert L; Kamp JC; Kuehnel MP; Warnecke A; Schambach A; Morgan M
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370779
[TBL] [Abstract][Full Text] [Related]
13. Next Generation CD44v6-Specific CAR-NK Cells Effective against Triple Negative Breast Cancer.
Raftery MJ; Franzén AS; Radecke C; Boulifa A; Schönrich G; Stintzing S; Blohmer JU; Pecher G
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240385
[TBL] [Abstract][Full Text] [Related]
14. MUC1 as a target for CAR-T therapy in head and neck squamous cell carinoma.
Mei Z; Zhang K; Lam AK; Huang J; Qiu F; Qiao B; Zhang Y
Cancer Med; 2020 Jan; 9(2):640-652. PubMed ID: 31800160
[TBL] [Abstract][Full Text] [Related]
15. Assessing the Impact of Targeting CEACAM1 in Head and Neck Squamous Cell Carcinoma.
Tam K; Schoppy DW; Shin JH; Tay JK; Moreno-Nieves U; Mundy DC; Sunwoo JB
Otolaryngol Head Neck Surg; 2018 Jul; 159(1):76-84. PubMed ID: 29436278
[TBL] [Abstract][Full Text] [Related]
16. Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
Crist M; Yaniv B; Palackdharry S; Lehn MA; Medvedovic M; Stone T; Gulati S; Karivedu V; Borchers M; Fuhrman B; Crago A; Curry J; Martinez-Outschoorn U; Takiar V; Wise-Draper TM
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36328378
[TBL] [Abstract][Full Text] [Related]
17. Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines.
Lee J; Keam B; Park HR; Park JE; Kim S; Kim M; Kim TM; Kim DW; Heo DS
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5705-5715. PubMed ID: 36547689
[TBL] [Abstract][Full Text] [Related]
18. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
19. Landscape of natural killer cell activity in head and neck squamous cell carcinoma.
Charap AJ; Enokida T; Brody R; Sfakianos J; Miles B; Bhardwaj N; Horowitz A
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428584
[TBL] [Abstract][Full Text] [Related]
20. Engineering a single-chain variable fragment of cetuximab for CAR T-cell therapy against head and neck squamous cell carcinomas.
Haist C; Poschinski Z; Bister A; Hoffmann MJ; Grunewald CM; Hamacher A; Kassack M; Wiek C; Scheckenbach K; Hanenberg H
Oral Oncol; 2022 Jun; 129():105867. PubMed ID: 35468475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]